flavoxate (urispas) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Flavoxate is a drug, indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate is not indicated for definitive treatment, but is compatible with drugs used for the treatment of urinary tract infections. It was approved for use in the United States in 1970 and continues to be used. Drug acts as a direct antagonist at muscarinic acetylcholine receptors in cholinergically innervated organs. Its anticholinergic-parasympatholytic action reduces the tonus of smooth muscle in the bladder, effectively reducing the number of required voids, facilitating increased volume per void. Common side effects are those of parasympathetic stimulation and include dryness of the mouth and eyes, decreased sweating, headache, visual blurring, constipation, urinary retention, impotence, tachycardia and palpitations, anxiety, restlessness and in some instances agitation and delusions.   NCATS

Chemistry

  • SMILES: Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O
  • InChIKey: SPIUTQOUKAMGCX-UHFFFAOYSA-N
  • Mol. Mass: 391.47
  • ALogP: 4.41
  • ChEMBL Molecules:
    flavoxate  
    flavoxate hydrochloride  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.2791 - $0.8710
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-(1-piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4h-chromene-8-carboxylate | 2-piperidinoethyl 3-methyl-4-oxo-2-phenyl-4h-1-benzopyran-8-carboxylate | 2-piperidinoethyl 3-methylflavone-8-carboxylate | beta-piperidinoethyl 3-methylflavone-8-carboxylate | dw-61 | flavoxate | flavoxate hci | flavoxate hcl | flavoxate hydrochloride | flavoxato | flavoxatum | urispas | urispas 200

Organizations (7)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (5)


 

Cystitis (approved 2004)

Dysuria

Prostatitis (approved 2004)

Urethritis (approved 2004)

Urinary Tract Infections

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Healthy Volunteers (Phase 1)

Pain (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue